Director Ron Mayron filed a Form 4 with the SEC on November 2, 2026, reporting the acquisition of 166,577 restricted share units in IceCure Medical Ltd., listed on NASDAQ:ICCM, following shareholder approval of the grant on that same date.

Key Highlights

  • Transaction: Ron Mayron acquired 166,577 ordinary shares in the form of RSUs at a price of $0 on November 2, 2026.
  • Grant date: The RSUs were originally granted on August 11, 2026, and vested immediately upon shareholder approval on November 2, 2026.
  • Post-transaction holdings: Following the transaction, Mayron beneficially owns 176,464 securities in total, comprising 333 ordinary shares and 176,131 RSUs.
  • Vesting status: Of the 176,131 RSUs, 5,374 have vested and 170,757 remain unvested as of November 2, 2026.
  • Reverse split adjustment: Holdings have been adjusted to reflect IceCure Medical's 1-for-30 reverse share split effected on June 4, 2026.
  • Role: Mayron is identified in the filing as a Director of IceCure Medical Ltd.

IceCure Medical Director Ron Mayron's RSU Grant and Vesting Details

According to the Form 4 filed on November 2, 2026, Ron Mayron, a Director of IceCure Medical Ltd. (NASDAQ:ICCM), reported the acquisition of 166,577 restricted share units (RSUs) at no cost. The filing states that these RSUs were originally granted on August 11, 2026, and that all 166,577 RSUs vested immediately upon shareholder approval of the grant on November 2, 2026.

Following this transaction, the filing reports that Mayron beneficially owns a total of 176,464 securities on a direct basis. This total consists of 333 ordinary shares and 176,131 RSUs. The filing further specifies that of those RSUs, 5,374 have vested and 170,757 remain unvested as of November 2, 2026. The filing notes that these holdings have been adjusted to reflect the company's 1-for-30 reverse share split, which was effected on June 4, 2026.

The transaction is coded as an acquisition (Code A) under Table I - Non-Derivative Securities. No derivative securities transactions were reported in Table II. The filing was made by one reporting person, and no amendment to a prior filing is indicated.

What Was Disclosed

Ron Mayron, a Director at IceCure Medical Ltd., disclosed the acquisition of 166,577 RSUs at $0 that vested upon shareholder approval on November 2, 2026, bringing his total beneficial ownership to 176,464 securities, adjusted for a prior 1-for-30 reverse share split.